How to read your FDA Pre-Submission meeting minutes

The meeting itself is over in an hour. What actually shapes your submission months later is a document FDA sends afterward — the meeting minutes — and that document, not your memory of the room, is the record a reviewer will hold you to.

What the minutes are, and what they aren’t

A Pre-Submission is one meeting type under FDA’s Q-Submission Program, and the minutes that follow it are built the same way every Q-Sub’s minutes are: FDA works through the questions your Pre-Sub package actually asked, in order, and records its response to each one. That structure matters more than it looks like it should. If a topic came up in conversation but was never posed as a clear, written question in the package, don’t expect it to generate a documented answer — and don’t assume silence on it means agreement. FDA’s own goal under the Q-Submission guidance is to issue the minutes within 30 days of the meeting, fast enough that most sponsors treat the wait as a formality and read the document quickly once it lands. That’s the wrong instinct. The minutes are what you’ll cite in the actual submission’s cover letter, what a reviewer will pull up if your approach looks different from what was discussed, and the closest thing to a written commitment this process produces. Reading them once, quickly, the week they arrive is not the same as reading them the way you’ll need to months later when the submission is actually due.

Reading the verbs, not just the answers

The single most useful skill in reading a minutes document is noticing which verb FDA used for each response, because the verbs are doing real work. “Agreed” is the closest thing to alignment you’ll get — FDA reviewed your specific proposal and confirmed it. “Acknowledged” means FDA registered what you said without endorsing it; a reviewer later in the process is free to revisit it. “Would not object” sits in between — permissive, but not a commitment, and worth treating as conditional on nothing else changing. “Recommend” is FDA telling you its preference, which you can deviate from with justification, but deviating without one is a choice you’re making with your eyes open. And “unable to comment without additional information” is not a soft yes — it’s an open question you still have to close, usually by asking again in a follow-up Q-Sub rather than guessing. The other thing worth checking on a second read: whether your actual submission still matches what the minutes describe. Minutes are tied to the proposal as you presented it at the time. If the design, the testing plan, or the indications changed materially between the Pre-Sub and the real filing, the parts of the minutes that covered the old version aren’t protecting you anymore, and a reviewer working from the file in front of them will notice the gap before you do.

None of this changes how you prepare for the meeting itself, which is still mostly about asking the two or three questions where a wrong guess is expensive. What changes is what you do with the answer once you have it in writing — treat the minutes as a document you’ll reread on the day you finalize the submission, not just on the day they arrive.